David A. Reardon, MD, is a Professor of Medicine at Harvard
Medical School and currently serves as Clinical Director of the Center for
Neuro-Oncology at the Dana-Farber Cancer Institute.
He previously served as the Associate Deputy Director of the
Preston Robert Tisch Brain Tumor Center at Duke University Medical Center for
eleven years. He completed his residency at John Hopkins Hospital in Maryland,
USA and was awarded a fellowship at the University of Michigan. Dr. Reardon is
an active researcher with special interests in the design and implementation of
clinical trials for neuro-oncology and the preclinical evaluation of promising
therapeutics for central nervous system tumors.
His work includes using innovative clinical therapeutic agents to
improve outcome for patients with brain and spinal tumors, with particular
focus on immunotherapeutics. He has also led investigations of
molecular-targeting agents, anti-angiogenic reagents, cytotoxins and other
biologically-based therapies.
Dr. Reardon has published over 290 peer-reviewed manuscripts. He
received the R. Wayne Rundles Award for Excellence in Cancer Research as well
as the Award for Excellence in Adult Clinical Research by the Society for
Neuro-Oncology in 2015 and 2016. He also served as the tenth president of the
Society for Neuro-Oncology from 2013-2015.
Research Interest: Innovative Clinical Therapeutic Agents
To Improve Cure Rates In Patients With Brain And Spinal Tumors, With Particular
Focus On Immunotherapeutics As Well As Molecular-Targeting Agents,
Anti-Angiogenic Reagents, Cytotoxins And Other Biologically-Based Therapies.
PTZ: We're glad you're here. Please click "create a new query" if you are a new visitor to our website and need further information from us.
If you are already a member of our network and need to keep track of any developments regarding a question you have already submitted, click "take me to my Query."